Navigation Links
New Research Uncovers Elusive Target of Antifungal Agent
Date:6/13/2010

A research team in Japan has uncovered the mechanism underlying the antifungal activity of theonellamide (TNM), a bioactive compound found in a species of marine sponge. The finding, reported in Nature Chemical Biology, provides new insights toward the development of antifungal drugs, with broader applications to drug analysis in areas such as cancer research.

(PRWeb UK) June 13, 2010 -- A research team in Japan has uncovered the mechanism underlying the antifungal activity of theonellamide (TNM), a bioactive compound found in a species of marine sponge. The finding, reported in Nature Chemical Biology, provides new insights toward the development of antifungal drugs, with broader applications to drug analysis in areas such as cancer research.

Designing drugs that target fungal cells poses serious challenges due to their similarity to human cells at the molecular level. To avoid damaging human cells, such drugs exploit differences between mammalian and fungal cells, both of which, unlike bacteria, are in the same family of eukaryotes. The difficulty of this task results in toxic side effects and a shortage of effective antifungal agents.

The research team, headed by scientists at the RIKEN Advanced Science Institute, set out to tackle this problem by investigating the antifungal activity of theonellamides (TNMs), bicyclic peptides found in the marine sponge Theonella, on the fission yeast. Combining chemical-genetic profiling and biochemical and cellular analysis, they deduced that TNMs bind to a class of lipid molecules (3?-hydroxysterols) in the cell membrane to induce overproduction of 1,3-?-D-glucan, a component of the cell wall.

Antifungal activity in TNMs, the researchers showed, is thus different from other antifungals, which cause damage by impairing wall synthesis. Instead, TNMs damage fungal cells by abnormally promoting such synthesis, targeting not proteins as previously thought, but a class of lipids, including ergosterol. TNMs thus represent an entirely new class of sterol-binding molecules, offering a new direction in the development of antifungal agents and a powerful tool for drug analysis.

For more information, please contact:

Dr. Minoru Yoshida
Chemical Genomics Research Group
RIKEN Advanced Science Institute
Tel: +81-(0)48-467-9516 / Fax: +81-(0)48-467-4676

Ms. Tomoko Ikawa (PI officer)
Global Relations Office
RIKEN
Tel: +81-(0)48-462-1225 / Fax: +81-(0)48-462-4715

# # #

Read the full story at http://www.prweb.com/releases/2010/06/prweb4131144.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. New research identifies modifiable risk factors for heart disease
2. Nuvo Research announces early redemption of 5% convertible debentures
3. Researcher to track spread of disease, malware and power outages
4. UCSF Researchers Identify Regulator of Human Sperm Cells
5. Octapharma Accepting Applications for Research Grants Through March 31
6. Valentine Tailgate Party for the Girls with Festive Ideas from Beauty Research
7. New Research Shows Genes of Pregnant Women and Their Fetuses Can Increase the Risk of Preterm Labor
8. University of Maryland chemist receives Astellas Award for blindness prevention research
9. Developing a cyberinfrastructure for comparative effectiveness in cancer research
10. Women should be allowed to eat, drink during labor: Queens University researcher
11. Parkinsons disease research uncovers social barrier
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Research Uncovers Elusive Target of Antifungal Agent
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... 12, 2017 , ... On Saturday, October 21, the Health & Wellness Center ... to raise money for the American Heart Association Heart Walk. Teams of up to ... together to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology: